SHH and metabolic dysfunction-associated steatotic liver disease: The pilot study assessed whether SHH quantity indicates severity of the disease as determined by circulating cytokeratin 18 (M65), its caspase degradation product (M30) which have been shown to correlate with histologic severity in NAFLD [17, 18] as well as pathologic evaluations.